) and replicated findings from previous genetic associations of vWF levels in humans. Expression quantitative trait locus analyses demonstrate that most associated ABO single-nucleotide polymorphisms were also associated with vWF gene expression. Conclusions-Elevated vWF levels are associated with recurrent stroke in VISP. In the VISP population, genetic determinants of vWF levels that impact vWF gene expression were identified. These data add to our knowledge of the pathophysiologic and genetic basis for recurrent stroke risk and may have implications for clinical care decision making. (Stroke.
M
any genetic and epidemiologic studies have investigated factors affecting risk of first ischemic stroke. Fewer studies have focused on recurrent ischemic stroke as an outcome. After a first ischemic stroke, the risk for recurrence is increased 9-fold over the incident stroke risk for the general population. 1 Recurrent strokes more frequently disable or kill individuals than first-ever strokes. Young and middle-aged individuals (<50 years) with recurrent stroke have an observed mortality ≈14-fold higher than the expected mortality in age-matched nonstroke controls. 2 Further, mortality resulting from stroke recurrence among older individuals (>65 years) is increased between 2-and 4-fold. 1 Although established as a risk factor for first stroke, 3 the effect of elevated von Willebrand factor (vWF) levels on recurrent stroke risk remains underinvestigated. We hypothesize that expanding our knowledge of both vWF levels and genetic determinants of vWF levels influence recurrent stroke risk and could aid future clinical practice.
Background and Purpose-von Willebrand factor (vWF) plays an important role in thrombus formation during cerebrovascular damage. We sought to investigate the potential role of circulating vWF in recurrent cerebrovascular events and identify genetic contributors to variation in vWF level in an ischemic stroke population. Methods-We analyzed the effect of circulating vWF on risk of recurrent stroke using survival models in the VISP trial (Vitamin Intervention for Stroke Prevention) and the use of vWF in reclassification over traditional factors. We conducted a genome-wide association study) with imputation, based on 1000 Genomes Project data, for circulating vWF levels and then interrogated loci previously associated with vWF levels. We performed expression quantitative trait locus analysis for vWF across different tissues. Results-Elevated vWF levels were associated with increased risk for recurrent stroke in VISP. Adding vWF to traditional clinical parameters also improved recurrent stroke risk prediction. We identified single-nucleotide polymorphisms significantly associated with circulating vWF at the ABO locus (P<5×10 vWF is a multimeric glycoprotein expressed in endothelial cells and megakaryocytes. 4 ,5 vWF has 2 major roles in hemostasis, although its role is thought to be broad 6 : first, it acts as a carrier of factor VIII in plasma and second, it aids in platelet function which includes adhesion to the subendothelium, platelet-to-platelet interactions, and platelet aggregation in vessels that have undergone elevated shear stress. Even though high plasma levels of vWF predict stroke risk, 7, 8 the direct relationship between vWF and ischemic stroke is less well understood. 3 Our research on vWF levels, associated genes, and recurrent stroke risk uses samples and data from the VISP clinical trial (Vitamin Intervention for Stroke Prevention). The VISP biomarker and genetic subsample 9 consists of n=1931 individuals >35 years of age who had a nondisabling ischemic stroke and total homocysteine (Hcy) levels in the top quartile of the general population (Table 1) . For this subset, we merged data on vWF protein levels with genome-wide genotyping data (dbGaP [the database of Genotypes and Phenotypes] Study Accession: phs000343.v2.p1). We aimed to explore a possible role for vWF in recurrent stroke risk and investigate genomic loci that contribute to variation of vWF levels.
Materials and Methods

Study Population
VISP was a randomized controlled clinical trial of B-vitamin supplementation to prevent recurrent stroke, myocardial infarction, or death. 9 All participants enrolled in the VISP trial were diagnosed with a nondisabling ischemic stroke and had hyperhomocysteinemia. Subtype classification was not performed in the VISP trial. Detailed inclusion/exclusion criteria can be found in the study by Toole et al 9 .
All participants in VISP provided informed consent for the proposed study, and the study was approved by site institutional review boards.
vWF Measurement
vWF activity was measured in citrated plasma using ELISA using standard manufacturer's protocols (IMUBIND vWF Activity; American Diagnostica, Inc, Greenwich, CT).
Genetic Analyses
A detailed description of genotyping methods can be found in previous reports. 10, 11 We conducted a genome-wide test of association between vWF level and single-nucleotide polymorphism (SNP) in 1931 unrelated individuals included in the genetic subsample of VISP. Analyses were conducted with PLINK v1.0.7 12 using multivariable linear regression modeling. We adjusted for age, sex, and population structure using the first 10 principal components derived from genotype data using KING software (Wei-Min Chen; http://people. virginia.edu/≈wc9c/KING/).
13
Expression Quantitative Trait Locus Analysis
Expression quantitative trait loci analyses were performed using data from the Gene Tissue Expression Project (GTEx). Expression quantitative trait locus analyses were performed by testing rs505922 against all mRNAs in all tissues (GTEx http://gtexportal.org/home/ snp/rs505922). Next, we tested rs505922 specifically against vascularrelated tissues and ABO and vWF mRNA using the Test your own function found at GTEx http://www.gtexportal.org/home/testyourown.
Survival Analyses of Recurrent Stroke and All-Cause Mortality
The associations between vWF levels and time to recurrent stroke/ mortality during the trial or SNPs and time to recurrent stroke/ mortality during the trial were performed using Cox proportional hazards models. There were 182 individuals with stroke recurrence during the study follow-up period and 108 individuals who died of all-cause mortality (total n=2014). Time was measured from the time of randomization (high-or low-dose B vitamins). Censoring occurred because of the loss of follow-up, unexplained death, and early termination. SNPs were coded using additive genetic models. Clinical site was treated as a strata variable. We used 2 models: a basic model adjusting only for the intervention group (high-or low-dose B vitamins) and a full model adjusting for the intervention group, age, race, sex, smoking, body mass index, diabetes mellitus status, hypertension, and low-density lipoproteins.
Variance Analysis
Variance explained by SNP rs505922 was conducted using the statistical computing software R.
14 The R code for this analysis can be found at https://osf.io/9y3k8/.
Area Under the Receiver Operating Characteristic Curve, Net Reclassification Improvement, and Integrated Discrimination Improvement Analyses
Area under the receiver operating characteristic curve was used to assess the ability of demographic variables and the vWF level to predict for recurrent stroke. This value was estimated using the entire cohort and 100 bootstrapped samples to reduce the possibility of overfitting. Reclassification of recurrent stroke risk between the 2 nested models (demographic variables with or without vWF level) was calculated based on predicted values from regression models. Net reclassification improvement (NRI) was used to measure the degree to which recurrent stroke risk was appropriately reclassified. 15 Each risk result was classified into low-risk (<0.06), intermediaterisk (0.06<0.09), or high-risk (≥0.09) categories. Because the cutoff points may affect the result for the categorical NRI, the continuous NRI was also calculated. 16 The integrated discrimination improvement calculated the difference in discrimination slopes between the 2 nested models. 17 The SAS macro can be found here: Nancy Cook's Risk Prediction Modeling (Division of Preventative Medicine; http:// ncook.bwh.harvard.edu/sas-macros.html).
Results
We investigated the influence of vWF levels on recurrent stroke and all-cause mortality. Elevated vWF increases (per SD) risk for stroke recurrence in both our unadjusted (P=0.0007; hazard ratio, 1.26) and fully adjusted (P=0.018; hazard ratio, 1.19) models. Elevated vWF was also found to be associated with all-cause mortality in the unadjusted (P=0.0122; hazard ratio, 1.21) but not the adjusted model (P=0.263; hazard ratio, 1.10) in the VISP stroke population ( Table 1 ). The positive association between vWF and recurrent stroke prompted us to investigate the genetic determinants of vWF variation in VISP.
Our genome-wide association studies (GWAS) identified 146 SNPs within or near the ABO locus that reached our predefined significance cutoff of P=5x10 −8 ( Figure 1 ; Table I in the online-only Data Supplement). Our most strongly associated SNP, rs505922 (P=2.32×10 −30 ; variance explained, 6%), was previously associated with vWF levels in the general population (Table 2; Table I in the online-only Data Supplement). 18 Further, we assessed the use of vWF levels and ABO SNP rs505922 in recurrent stroke prediction over conventional risk factors (CFs) using those taken from the Essen Risk Score using NRI, integrated discrimination improvement, receiver operating characteristic curves. The results of these analyses can be found in Table II and Figure I in the online-only Data Supplement. We confirmed that in all conditions (CF versus CF+vWF, CF versus CF+rs505922, and CF versus CF+vWF+rs505922), vWF remains significantly associated with increased risk for recurrent stroke over traditional risk measures. The traditional model adjusted for treatment group, diabetes mellitus status, hypertension, smoking, age, and history of stroke. When vWF was added to the risk model, it improved discrimination; the C statistics increased from 0.635 to 0.648 based on logistic regression models. A significantly higher percentage of participants were reclassified appropriately than inappropriately, with the net reclassification benefit measured by NRI of 10.6% (P=0.0028). The integrated discrimination improvement was 0.004 (P=0.0388). With 100 bootstrap samples, the category-free NRI was 19.7% (P=0.0113), indicating that there was a 19.7% net improvement in the predictions of recurrent stroke. The integrated discrimination improvement was 0.004 (95% confidence interval, 0.0004-0.0087 from bootstrap samples; P=0.1014 assumes normality). We further investigated the prediction ability using a survival model. With the 100 bootstrap samples, the average difference of the 2 C statistics was 0.006 (P<0.0001). Overall, this shows the addition of vWF does improve the ability to predict recurrent stroke risk. The results of using the whole sample and bootstrap samples were consistent.
To limit confounding factors in these analyses, we also performed a comprehensive interaction analysis and showed that there is no significant interaction between total plasma Hcy (tHcy) or treatment arm in 7 different survival models that include both genetic and nongenetic covariates (all P>0.05). These include model parameters: original model+tHcy+tHcy×vWF, original model+treatment arm×vWF, original model+tHcy+treatment arm×vWF, original model+tHcy+rs505922+treatment arm×vWF, original model+tHcy+rs505922+tHcy×vWF, original model+tHcy+rs505922+treatment arm×rs505922, and original model+tHcy+rs505922+tHcy×rs505922. Data not shown.
We sought to determine whether our remaining most significantly associated SNPs had also been reported in previous genetic studies of vWF levels and other vascular traits as defined by the NHGRI-EBI genome-wide association study catalogue (http://www.ebi.ac.uk/gwas/). Five of our top SNPs replicated previous findings in genetic studies of vWF levels, and 6 were found to have been significantly associated with vascular traits ( Table 2 ). Ten of our significantly associated SNPs had been previously reported as associated with one or more traits (Table III in the onlineonly Data Supplement). Next, using a candidate gene approach, we identified regions that were previously associated with vWF levels, or vWF with venous thrombosis, and interrogated the current analysis for significance. We found positive associations with rs732505, 19 identified in a combined analysis of 2 genomewide association study reports of vWF (Table 3) ). To determine whether our significantly associated SNPs influence tissue-specific mRNA expression of ABO and vWF, we performed expression quantitative trait locus analyses. Using the GTEx V6 data set, we found that rs505922 was significantly associated with ABO expression levels in 15 tissues, with the highest effect size in skeletal muscle (P=2.7×10−32; effect size, 0.80) when tested against all mRNA transcripts (Table 4) . Interestingly, rs505922 was also associated with vWF mRNA levels in lung (P=0.04; effect size, 0.12). Given the source of vWF measures in VISP (whole blood), we tested rs505922 specifically for an effect on ABO expression in only whole blood and found the association remained, although with an effect size in the opposite direction of skeletal muscle (P=7×10 −4 ; effect size, −0.27).
Finally, we investigated whether there was shared genetic variation at the ABO locus that not only contributed to vWF levels but also recurrent stroke. Even though elevated vWF protein levels increased the risk for stroke recurrence and ABO SNPs influence vWF mRNA levels, there was no independent relationship between significant ABO genome-wide association study SNPs and recurrent stroke prediction.
Discussion
In the current study, we investigated the relationship between vWF and recurrent stroke risk in the VISP population. Individuals with high vWF levels in VISP have an increased risk for stroke recurrence using both basic and more comprehensively adjusted survival analyses. vWF may play a role in all-cause mortality but when assessed in the fully adjusted model, these findings become unclear. These results suggest that vWF levels may represent a novel and independent risk factor for recurrent ischemic stroke, even after accounting for known risk factors, such as smoking, body mass index, and hypertension. This raises the question as to whether measuring vWF after an acute ischemic stroke might provide meaningful risk stratification of stroke recurrence in the clinical setting.
Using a GWA approach for recurrent ischemic stroke, we identified a previously known locus for vWF at the ABO locus, including rs505922 that has been previously identified as associated with ischemic stroke, venous thromboembolism, and factor VIII levels ( Table 3; Table I in the online-only Data Supplement). [19] [20] [21] The EuroCLOT study identified this same SNP as associated with vWF, stroke, large vessel, and cardioembolic stroke. 18 Additional ABO SNPs have been associated with vascular outcomes, including venous thromboembolism, ischemic stroke, and coronary heart disease ( Table 3; Table III in the online-only Data Supplement), indicating a major role for this gene in the pathophysiology of vascular disease.
Based on a comprehensive literature search, we investigated loci other than ABO that influence vWF levels. Although these loci did not reach genome-wide significance in our initial analyses, using a post hoc candidate SNP lookup approach, we detected associations with reported loci in the VISP population. We not only replicated previous finding of an association of vWF levels with the vWF gene but also confirmed association between vWF levels and ADAMTS13, OBP2B, C9orf96, and SURF6 ( Table 3 ), suggesting that these loci may influence vWF levels even in the setting of postacute ischemic stroke even though our analysis might simply have been underpowered to identify these associations in the primary investigation. However, we must also investigate the possibility that these genes simply are not associated with vWF in the VISP study participants for the tissue investigated. Although this study has identified a potentially useful biomarker in stratification of patients with risk for stroke recurrence, it is not without limitations. For example, our study includes a low proportion of individuals of non-European descent, potentially limiting generalizability. Stroke subtype information is not available for VISP; however, given that atrial fibrillation was an exclusion criterion, we speculate that the majority of qualifying strokes in VISP were caused by small-vessel disease, intracranial atherosclerosis, or cryptogenic mechanisms. 11 The exclusion of most extracranial large artery and cardioembolic strokes from VISP contrasts with the EuroCLOT study that found an association between an ABO SNP and these stroke mechanisms. 18 Also, although the GTEx project is the largest resource of its kind, numbers of individuals per tissue are limited, and further analyses should and will be performed. Finally, there may truly be no association with VISP participants and the loci which failed to replicate which provides important information to the community given the homogenous nature of this population.
We show a novel association between vWF levels and recurrent stroke risk and confirmed reported genetic associations with vWF in an ischemic stroke population. Finally, we found that several of the associated variants in the ABO gene seem to be tissue-specific drivers of gene expression levels, furnishing a plausible mechanism of association. In summary, we believe these data warrant further investigation to determine whether vWF and its determinants might help in stratifying risk of stroke recurrence in ischemic stroke patients. We strongly believe this warrants further investigation and could influence clinical care if validated.
